Innovative Industrial Properties (IIPR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Generated Q1 2025 revenues of $71.7 million and AFFO of $55.3 million, with net income attributable to common stockholders of $30.3 million, ending with over $220 million in liquidity.
Owns 110 properties in 19 states, focused on cannabis-related real estate, with 98.4% leased as of March 31, 2025, and a weighted-average lease term of 13.5 years.
Q1 2025 marked by tenant defaults (PharmaCann, 4Front, Gold Flora, TILT), leading to lease defaults, application of security deposits, and legal remedies.
Strategic shift underway to refresh tenant base, optimize occupancy, and improve financial stability and growth.
Repurchased $20 million of common stock and retired nearly $9 million of debt at a discount.
Financial highlights
Q1 2025 revenues were $71.7 million, down 6.5% sequentially and 5% year-over-year, mainly due to tenant defaults and lease terminations.
AFFO was $55.3 million ($1.94/share), a 13% decrease from Q4 2024 and 12% year-over-year.
Net income attributable to common stockholders was $30.3 million, down from $39.1 million in Q1 2024.
Applied $5.8 million of security deposits for rent payments from defaulted tenants; these deposits are now exhausted.
Declared dividends: $1.90 per common share and $0.5625 per Series A preferred share.
Outlook and guidance
Management expects the tenant refresh and retenting process to play out over the next 18–36 months amid continued challenges from tenant financial health, regulatory uncertainty, and market dynamics.
Confident in the ability to stabilize the portfolio and capitalize on new investment opportunities as market conditions evolve.
Liquidity expected to be sufficient through cash on hand, operations, and available credit.
Latest events from Innovative Industrial Properties
- Q2 revenue up 4% to $79.8M, net income $41.7M, AFFO $2.29/share, and dividend raised 4.4%.IIPR
Q2 20248 Jul 2026 - Q3 2024 revenue was $76.5M with 95.7% occupancy and strong liquidity despite industry headwinds.IIPR
Q3 20248 Jul 2026 - Q1 2026 revenue was $69M, but tenant defaults and debt maturity threaten ongoing viability.IIPR
Q1 20265 May 2026 - Diversified REIT with robust growth, strong balance sheet, and expanding life sciences exposure.IIPR
Investor presentation5 May 2026 - 2025 featured robust financials, strategic diversification, and strong governance ahead of key shareholder votes.IIPR
Proxy filing23 Apr 2026 - 2025 revenues hit $266M; life sciences investment and leasing drive growth amid tenant challenges.IIPR
Q4 202524 Feb 2026 - 2024 revenue steady at $308.5M; strong liquidity, high occupancy, and PharmaCann lease resolution.IIPR
Q4 202423 Dec 2025 - 2024 saw record revenue, strong governance, and enhanced ESG and compensation practices.IIPR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.IIPR
Proxy Filing1 Dec 2025